Developer docs
API playgroundTry for free, no card

Search company profiles

Oncosoft

Full company profile

uuid0002rop

Namestring
Oncosoft
Legal namestring
Oncosoft Inc.
Websiteurl
oncosoft.io
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Oncosoft is a Seoul-based medical AI company developing software for radiation oncology, founded in 2019 by Jin Sung Kim, a Professor of Radiation Oncology at Yonsei University College of Medicine. The company's core product, OncoStudio, performs AI-based automated contouring of normal organs and clinical target volumes from CT and MRI images for radiation therapy treatment planning, processing over 10 million contours for more than 213,000 patients across 100+ hospitals globally. The proprietary technology combines 2D and 3D deep learning with Large Language Model integration for multimodal analysis that incorporates clinical text (disease stage, tumor location, surgical history) alongside imaging data, achieving 2.36x higher accuracy than imaging-only models in external validation. The product suite includes OncoStudio (auto-contouring), OncoFlow (radiotherapy workflow management), OncoPlan (particle therapy treatment planning, in development), OncoRPT/OncoRLT (radiopharmaceutical and radioligand therapy workflow, in development), and OncoVet (veterinary radiation therapy, approved April 2025).

Oncosoft generates revenue primarily through annual or multi-year subscription licenses for hospital deployment, with first commercial revenue in the US and Japan achieved in December 2025. The go-to-market combines direct enterprise sales (Korea, US via Dallas, TX subsidiary established August 2023) with channel partnerships (Anzai Medical holds exclusive Japan distribution rights; M3 AI provides marketing network access in Japan). Regulatory clearance across Korea (MFDS, February 2022), US (FDA 510(k), February 2025), Japan (PMDA, April 2025), Singapore (October 2025), and Brazil (December 2025) enables multi-market commercialization, supported by ISO 13485, ISO 27001, and ISO 27701 certifications. Customers include major Korean cancer centers (Samsung Seoul Hospital, Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Hospital), Mayo Clinic (US flagship, 10 licenses), and research institutions in Japan and Singapore.

The company has raised approximately 150 billion KRW (~$112M USD) cumulatively across seed, pre-A, Series A (35B KRW in September 2022), and Series B (11B KRW in September 2024) rounds, with investors including BNH Investment, HB Investment, Devsisters Ventures, BonAngels Venture Partners, and LB Investment. Total headcount is 11-50, with leadership comprising CEO Jin Sung Kim, CTO Han Joo Chae, CPO Seonggong Moon, CFO Yeonkyung Lee, and Sales Director Do-il Jung, plus three medical advisors. Oncosoft is targeting an IPO in 2026 and has executed pre-IPO corporate actions including a stock split (November 2024), third-party share allocation, and free share distribution.

Short descriptiontext

Oncosoft is a Seoul-based medical AI company that develops AI-powered auto-contouring and workflow management software (OncoStudio, OncoFlow) for radiation oncology departments in hospitals. Its solutions serve radiation oncologists and medical physicists across 100+ hospitals globally, reducing manual organ delineation from hours to minutes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiation oncology software, AI auto-contouring, radiotherapy workflow, medical imaging AI, treatment planning software
Industry4 codes
PRIMARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAC
Radiation Oncology
NAICS code3 codes
  • Diagnostic Imaging Centers621512
  • Medical and Diagnostic Laboratories6215
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiation Oncology AI Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Software Licenses (OncoStudio, OncoFlow)
TypeSubscription Recurring
Description

Annual or multi-year license fees for AI contouring and workflow management software. Revenue recognized from hospital deployments in Korea (20+ hospitals), US (Mayo Clinic), Japan, Singapore, and other markets. First commercial revenue in US and Japan achieved December 2025.

oncosoft.io
2Treatment Planning Systems (OncoPlan)
TypeSubscription Recurring
Description

Treatment planning software for particle therapy (proton, heavy ion) under development. Planned commercialization by 2027 targeting particle therapy centers worldwide.

oncosoft.io
3Radiopharmaceutical Therapy (RLT) Platform
TypeSubscription Recurring
Description

Web-based platform for radioligand therapy planning and workflow management under development. Targets emerging RLT treatments including Pluvicto and future radiopharmaceuticals.

oncosoft.io
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise hospital licensing
ModelSubscriptionBilling cadenceAnnual
Notes

License fees for hospital deployment of OncoStudio and OncoFlow. Pricing not publicly disclosed; quote-based sales process.

oncosoft.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1OncoStudio
Description

AI-powered automatic contouring software for radiation therapy that automatically identifies and segments organs and tissues from CT and MRI images to support treatment planning

oncosoft.io
+4 more records
Core offering1 text field

Oncosoft develops and sells AI-based software for radiation oncology. Its core product OncoStudio performs automated contouring of normal organs and clinical target volumes from CT and MRI images, reducing contouring time from hours to about one minute per case. The company also offers OncoFlow for radiotherapy workflow management and is developing OncoPlan (particle therapy treatment planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoVet (veterinary radiation therapy) for sale to hospitals and cancer centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduces contouring time from hours to ~1 minute per case (10x faster)
+4 more records
Product overview1 text field

Oncosoft offers an end-to-end AI software ecosystem for radiation oncology, consisting of OncoStudio (AI auto-contouring) as the core commercial product, OncoFlow (workflow management) for treatment process integration, and pipeline products including OncoPlan (particle therapy planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoRLT (radioligand therapy). The portfolio also includes OncoVet for veterinary applications. The products work together to provide comprehensive coverage from automated organ segmentation through treatment planning and workflow management across the entire radiotherapy process.

Product and service5 records
1OncoStudio
CategoryRadiation Oncology AI Software
Description

AI-based automated contouring software that automatically segments normal organs and clinical target volumes from CT and MRI images for radiation therapy planning. Reduces contouring time from hours to approximately 1 minute per case while maintaining expert-level accuracy. Supports 190+ structures for head and neck, thorax, abdomen, and pelvis. Targeted at radiation oncology departments in hospitals and cancer centers globally.

2OncoFlow
CategoryRadiation Oncology AI Software
Description

Comprehensive radiotherapy workflow management platform that integrates the entire treatment process into one seamless system, eliminating errors and streamlining every treatment step from patient data management to treatment delivery. Targeted at hospital radiation oncology departments and cancer centers.

3OncoPlan
CategoryRadiation Oncology AI Software
Description

AI-guided treatment planning software for particle therapy that optimizes dose calculations using biophysical simulation, maximizing tumor control while minimizing damage to surrounding organs for proton and heavy ion radiotherapy. Targeted at particle therapy centers globally.

4OncoRPT
CategoryRadiation Oncology AI Software
Description

Radiopharmaceutical Therapy (RPT) workflow management platform providing personalized dosimetry and integrated patient monitoring to improve treatment precision and safeguard healthy tissues for emerging radiopharmaceutical treatments. Targeted at cancer centers offering radiopharmaceutical therapy.

5OncoVet (OncoBet)
CategoryVeterinary Radiation Therapy Software
Description

Veterinary radiation therapy software providing AI-based contouring and treatment planning for animal cancer patients in veterinary oncology settings. Targeted at veterinary hospitals and animal cancer centers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish public company specializing in radiation oncology treatment planning software (RayStation, RayCare). Direct competitor in radiation therapy software with global installed base across major cancer centers.

TypeDirect peer
Description

Finnish company providing AI-based auto-segmentation for radiation therapy planning. Closest direct competitor to OncoStudio in AI auto-contouring, with CE-marked and FDA-cleared products.

TypeDirect peer
Description

Canadian AI auto-contouring company (Limbus Contour) for radiation oncology. Direct competitor targeting the same hospital radiation oncology departments with similar AI segmentation products.

TypeDirect peer
Description

UK-based medical imaging AI company with products for radiation oncology workflow including auto-contouring and treatment planning. Direct peer in oncology imaging AI space.

TypeEmerging player
Description

French AI company applying deep learning to radiation oncology treatment planning and auto-contouring. Comparable emerging player targeting similar radiation oncology AI use cases in Europe.

TypeBroad incumbent
Description

Largest radiation oncology software and equipment vendor globally (now owned by Siemens Healthineers). Broad incumbent offering Ethos adaptive radiotherapy and Eclipse treatment planning with embedded AI features; Oncosoft has MOU partnership with Elekta but competes with Varian's full stack.

TypeBroad incumbent
Description

Global radiation therapy equipment and software vendor (Mosaiq, Versa HD, Unity MR-Linac). Oncosoft has an established MOU/partnership with Elekta; broad incumbent serving the same radiation oncology customers.

TypeEmerging player
Description

US-based radiation oncology automation software company (ClearCalc, AutoContour, EZFluence). Comparable peer providing AI-driven workflow automation tools to radiation oncology departments.

9MIM Software
TypeDirect peer
Description

US medical imaging analysis software company with products for radiation oncology including contouring and image registration. Direct peer in radiation oncology AI software with hospital channel.

10Pursuit Healthcare Advisors / Adaptiiv
TypeEmerging player
Description

Emerging players in radiation oncology software including 3D printing and AI-based planning tools. Adjacent to Oncosoft's expanding radiation therapy planning product portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncosoft

Radiation Oncology AI Softwareoncosoft.io

Oncosoft is a Seoul-based medical AI company that develops AI-powered auto-contouring and workflow management software (OncoStudio, OncoFlow) for radiation oncology departments in hospitals. Its solutions serve radiation oncologists and medical physicists across 100+ hospitals globally, reducing manual organ delineation from hours to minutes.

What Oncosoft does

Oncosoft is a Seoul-based medical AI company developing software for radiation oncology, founded in 2019 by Jin Sung Kim, a Professor of Radiation Oncology at Yonsei University College of Medicine. The company's core product, OncoStudio, performs AI-based automated contouring of normal organs and clinical target volumes from CT and MRI images for radiation therapy treatment planning, processing over 10 million contours for more than 213,000 patients across 100+ hospitals globally. The proprietary technology combines 2D and 3D deep learning with Large Language Model integration for multimodal analysis that incorporates clinical text (disease stage, tumor location, surgical history) alongside imaging data, achieving 2.36x higher accuracy than imaging-only models in external validation. The product suite includes OncoStudio (auto-contouring), OncoFlow (radiotherapy workflow management), OncoPlan (particle therapy treatment planning, in development), OncoRPT/OncoRLT (radiopharmaceutical and radioligand therapy workflow, in development), and OncoVet (veterinary radiation therapy, approved April 2025).

Oncosoft generates revenue primarily through annual or multi-year subscription licenses for hospital deployment, with first commercial revenue in the US and Japan achieved in December 2025. The go-to-market combines direct enterprise sales (Korea, US via Dallas, TX subsidiary established August 2023) with channel partnerships (Anzai Medical holds exclusive Japan distribution rights; M3 AI provides marketing network access in Japan). Regulatory clearance across Korea (MFDS, February 2022), US (FDA 510(k), February 2025), Japan (PMDA, April 2025), Singapore (October 2025), and Brazil (December 2025) enables multi-market commercialization, supported by ISO 13485, ISO 27001, and ISO 27701 certifications. Customers include major Korean cancer centers (Samsung Seoul Hospital, Seoul National University Hospital, Severance Hospital, Kangbuk Samsung Hospital), Mayo Clinic (US flagship, 10 licenses), and research institutions in Japan and Singapore.

The company has raised approximately 150 billion KRW (~$112M USD) cumulatively across seed, pre-A, Series A (35B KRW in September 2022), and Series B (11B KRW in September 2024) rounds, with investors including BNH Investment, HB Investment, Devsisters Ventures, BonAngels Venture Partners, and LB Investment. Total headcount is 11-50, with leadership comprising CEO Jin Sung Kim, CTO Han Joo Chae, CPO Seonggong Moon, CFO Yeonkyung Lee, and Sales Director Do-il Jung, plus three medical advisors. Oncosoft is targeting an IPO in 2026 and has executed pre-IPO corporate actions including a stock split (November 2024), third-party share allocation, and free share distribution.

Oncosoft firmographics

Firmographics
Name
Oncosoft
Legal name
Oncosoft Inc.
Website
https://oncosoft.io
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Oncosoft is a Seoul-based medical AI company that develops AI-powered auto-contouring and workflow management software (OncoStudio, OncoFlow) for radiation oncology departments in hospitals. Its solutions serve radiation oncologists and medical physicists across 100+ hospitals globally, reducing manual organ delineation from hours to minutes.
Ownership category
akta.pro rank

Oncosoft industry classification

Industry
Product category
Radiation Oncology AI Software
NAICS
Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (6215), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLALAGAH
Oncology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLAIAGAI
Nuclear Medicine Clinical Services & Therapy Centers
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAKAFAC
Radiation Oncology

Keywords

  • Radiation oncology software
  • AI auto-contouring
  • Radiotherapy workflow
  • Medical imaging AI
  • Treatment planning software

Where Oncosoft is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Oncosoft business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software Licenses (OncoStudio, OncoFlow): Annual or multi-year license fees for AI contouring and workflow management software. Revenue recognized from hospital deployments in Korea (20+ hospitals), US (Mayo Clinic), Japan, Singapore, and other markets. First commercial revenue in US and Japan achieved December 2025.
  2. Treatment Planning Systems (OncoPlan): Treatment planning software for particle therapy (proton, heavy ion) under development. Planned commercialization by 2027 targeting particle therapy centers worldwide.
  3. Radiopharmaceutical Therapy (RLT) Platform: Web-based platform for radioligand therapy planning and workflow management under development. Targets emerging RLT treatments including Pluvicto and future radiopharmaceuticals.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise hospital licensing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Oncosoft product offering

Product offering

Core offering

Oncosoft develops and sells AI-based software for radiation oncology. Its core product OncoStudio performs automated contouring of normal organs and clinical target volumes from CT and MRI images, reducing contouring time from hours to about one minute per case. The company also offers OncoFlow for radiotherapy workflow management and is developing OncoPlan (particle therapy treatment planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoVet (veterinary radiation therapy) for sale to hospitals and cancer centers.

Product overview

Oncosoft offers an end-to-end AI software ecosystem for radiation oncology, consisting of OncoStudio (AI auto-contouring) as the core commercial product, OncoFlow (workflow management) for treatment process integration, and pipeline products including OncoPlan (particle therapy planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoRLT (radioligand therapy). The portfolio also includes OncoVet for veterinary applications. The products work together to provide comprehensive coverage from automated organ segmentation through treatment planning and workflow management across the entire radiotherapy process.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoStudio: AI-powered automatic contouring software for radiation therapy that automatically identifies and segments organs and tissues from CT and MRI images to support treatment planning
  • OncoFlow
  • OncoPlan
  • OncoRPT
  • OncoVet

Products and services

  • OncoStudio AI-based automated contouring software that automatically segments normal organs and clinical target volumes from CT and MRI images for radiation therapy planning. Reduces contouring time from hours to approximately 1 minute per case while maintaining expert-level accuracy. Supports 190+ structures for head and neck, thorax, abdomen, and pelvis. Targeted at radiation oncology departments in hospitals and cancer centers globally.
  • OncoFlow Comprehensive radiotherapy workflow management platform that integrates the entire treatment process into one seamless system, eliminating errors and streamlining every treatment step from patient data management to treatment delivery. Targeted at hospital radiation oncology departments and cancer centers.
  • OncoPlan AI-guided treatment planning software for particle therapy that optimizes dose calculations using biophysical simulation, maximizing tumor control while minimizing damage to surrounding organs for proton and heavy ion radiotherapy. Targeted at particle therapy centers globally.
  • OncoRPT Radiopharmaceutical Therapy (RPT) workflow management platform providing personalized dosimetry and integrated patient monitoring to improve treatment precision and safeguard healthy tissues for emerging radiopharmaceutical treatments. Targeted at cancer centers offering radiopharmaceutical therapy.
  • OncoVet (OncoBet) Veterinary radiation therapy software providing AI-based contouring and treatment planning for animal cancer patients in veterinary oncology settings. Targeted at veterinary hospitals and animal cancer centers.

Quantifiable outcome

  • Reduces contouring time from hours to ~1 minute per case (10x faster)
  • +4 more outcomes

Companies that use Oncosoft

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

Oncosoft technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature6 records

Oncosoft partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Oncosoft competitors and assessment

Company assessment

Direct peers

  • RaySearch Laboratories: Swedish public company specializing in radiation oncology treatment planning software (RayStation, RayCare). Direct competitor in radiation therapy software with global installed base across major cancer centers.
  • MVision AI: Finnish company providing AI-based auto-segmentation for radiation therapy planning. Closest direct competitor to OncoStudio in AI auto-contouring, with CE-marked and FDA-cleared products.
  • Limbus AI: Canadian AI auto-contouring company (Limbus Contour) for radiation oncology. Direct competitor targeting the same hospital radiation oncology departments with similar AI segmentation products.
  • Mirada Medical: UK-based medical imaging AI company with products for radiation oncology workflow including auto-contouring and treatment planning. Direct peer in oncology imaging AI space.
  • MIM Software: US medical imaging analysis software company with products for radiation oncology including contouring and image registration. Direct peer in radiation oncology AI software with hospital channel.

Emerging players

  • TheraPanacea: French AI company applying deep learning to radiation oncology treatment planning and auto-contouring. Comparable emerging player targeting similar radiation oncology AI use cases in Europe.
  • Radformation: US-based radiation oncology automation software company (ClearCalc, AutoContour, EZFluence). Comparable peer providing AI-driven workflow automation tools to radiation oncology departments.
  • Pursuit Healthcare Advisors / Adaptiiv: Emerging players in radiation oncology software including 3D printing and AI-based planning tools. Adjacent to Oncosoft's expanding radiation therapy planning product portfolio.

Broad incumbents

  • Varian Medical Systems (Siemens Healthineers): Largest radiation oncology software and equipment vendor globally (now owned by Siemens Healthineers). Broad incumbent offering Ethos adaptive radiotherapy and Eclipse treatment planning with embedded AI features; Oncosoft has MOU partnership with Elekta but competes with Varian's full stack.
  • Elekta: Global radiation therapy equipment and software vendor (Mosaiq, Versa HD, Unity MR-Linac). Oncosoft has an established MOU/partnership with Elekta; broad incumbent serving the same radiation oncology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Customer concentration

Oncosoft social profiles

Digital presence

Oncosoft compliance and trust

Trust signal

Compliance8 records

Oncosoft financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncosoft leadership team

Management profile

Number of profiles

Profiles8 records

Oncosoft subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Oncosoft funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncosoft M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncosoft

What does Oncosoft do?

Oncosoft develops and sells AI-based software for radiation oncology. Its core product OncoStudio performs automated contouring of normal organs and clinical target volumes from CT and MRI images, reducing contouring time from hours to about one minute per case. The company also offers OncoFlow for radiotherapy workflow management and is developing OncoPlan (particle therapy treatment planning), OncoRPT (radiopharmaceutical therapy workflow), and OncoVet (veterinary radiation therapy) for sale to hospitals and cancer centers.

Is Oncosoft a public or private company?

Oncosoft is a private company. It is classified as venture growth investor backed and is currently operating.

When was Oncosoft founded?

Oncosoft was founded in 2019. It employs 11 to 50 people.

Where is Oncosoft based?

Oncosoft is headquartered in Seoul, South Korea, in the Asia region.

How does Oncosoft make money?

Three revenue lines are on record. Software Licenses (OncoStudio, OncoFlow) is the primary driver. The others are treatment Planning Systems (OncoPlan) and radiopharmaceutical Therapy (RLT) Platform.

Who are Oncosoft's main competitors?

Direct peers on record are RaySearch Laboratories, MVision AI, Limbus AI, Mirada Medical and MIM Software. Emerging players are TheraPanacea, Radformation and Pursuit Healthcare Advisors / Adaptiiv. Broad incumbents are Varian Medical Systems (Siemens Healthineers) and Elekta.

Does Oncosoft have an API?

No public API is recorded for Oncosoft.

What industry is Oncosoft in?

Oncosoft's product category is Radiation Oncology AI Software. Its primary akta.pro industry code is HLALAGAH, Oncology Telemedicine Platforms, with a secondary code of HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers. Its NAICS code is 621512 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageOncosoft named to the 2026 CB Insights’ 50 most promising digital health startupsOncosoft was named to CB Insights' 2026 Digital Health 50 for its AI-powered radiation oncology software. The company's OncoStudio received FDA clearance in 2025, and OncoPlan got Korea's first domestic carbon-ion TPS approval in August 2026. It plans to extend its technology to proton therapy and global clinics.SedailyOncosoft secures 11 billion won in Series B funding... "Full-scale global expansion"Oncosoft secured 11 billion won in Series B funding to support its global expansion and next-generation AI solution development. The round included participation from existing investors BNH Investment, HB Investment, and Devsisters Ventures, alongside new entrants Bon Angels Venture Partners and LB Investment. The company aims to achieve a public listing via technology special listing in 2026.VenturelabCollaborative success: Terapet's partnership with Yonsei University and Oncosoft Inc. secures multi-million funding from Innosuisse and KIATTerapet, in partnership with Yonsei University and Oncosoft Inc., secured multi-million funding from Innosuisse and KIAT to develop a personalized quality assurance device for Heavy Ion Therapy. The collaboration, officially launching on November 1st, 2023, aims to pioneer patient-specific quality assurance at South Korea's first carbon ion therapy center. This initiative is part of a bilateral innovation program between Switzerland and South Korea to promote knowledge exchange and business development.DealsiteBio venture catching cancer with AI secures 3 billion investmentOncoSoft, an AI-based bio venture focused on cancer treatment software, secured new investments worth 3 billion won amid a challenging investment landscape for bio ventures. The funding was part of a Series A round, with contributions from venture capitals HB Investment and BNH Investment. This marks a significant funding event for OncoSoft, which had not received new funding in over a year since its last investment round.